Redox Metabolism and Vascular Calcification in Chronic Kidney Disease

Biomolecules. 2023 Sep 20;13(9):1419. doi: 10.3390/biom13091419.

Abstract

Vascular calcification (VC) is a common complication in patients with chronic kidney disease which increases their mortality. Although oxidative stress is involved in the onset and progression of this disorder, the specific role of some of the main redox regulators, such as catalase, the main scavenger of H2O2, remains unclear. In the present study, epigastric arteries of kidney transplant recipients, a rat model of VC, and an in vitro model of VC exhibiting catalase (Cts) overexpression were analysed. Pericalcified areas of human epigastric arteries had increased levels of catalase and cytoplasmic, rather than nuclear runt-related transcription factor 2 (RUNX2). In the rat model, advanced aortic VC concurred with lower levels of the H2O2-scavenger glutathione peroxidase 3 compared to controls. In an early model of calcification using vascular smooth muscle cells (VSMCs), Cts VSMCs showed the expected increase in total levels of RUNX2. However, Cts VMSCs also exhibited a lower percentage of the nucleus stained for RUNX2 in response to calcifying media. In this early model of VC, we did not observe a dysregulation of the mitochondrial redox state; instead, an increase in the general redox state was observed in the cytoplasm. These results highlight the complex role of antioxidant enzymes as catalase by regulation of RUNX2 subcellular location delaying the onset of VC.

Keywords: CKD; DIGE; RUNX2; catalase; epigastric arteries; vascular calcification.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Catalase
  • Core Binding Factor Alpha 1 Subunit / genetics
  • Humans
  • Hydrogen Peroxide
  • Oxidation-Reduction
  • Rats
  • Renal Insufficiency, Chronic*
  • Vascular Calcification*

Substances

  • Catalase
  • Core Binding Factor Alpha 1 Subunit
  • Hydrogen Peroxide

Grants and funding

This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project RD12/0021/0023 and RD16/0009/0017, and RD21/0005/0019 and by Next Generation EU; Recovery, Transformation and Resilience Plan, and through the project PI11-00667, PI14/00707, PI17/00384, PI20/00633, PI20/00753 and PI22/00195 (co-funded by the European Union), Plan Estatal de I+D+I 2013–2016, Plan de Ciencia, Tecnología e Innovación 2013–2017 y 2018–2022 del Principado de Asturias (GRUPIN14-028, IDI-2018-000152, IDI/2021/000080). B.M.-C. and S.F.-V. were supported by a graduate fellowship from the Gobierno del Principado de Asturias (“Severo Ochoa” program): BP19-057, BP20-081, J.M.-V. by a graduate fellowship from the Ministerio de Ciencia, Innovación y Universidades (FPU program): FPU2019-00483, C.A.-M. by RICORS2040 (Kidney Disease), N.C.-L. by IDI-2018-000152 and IDI-2021-000080, and S.P. was supported by Fundación para la Investigación Biosanitaria de Asturias (FINBA).